4-Hydroxytamoxifen
SIAL/T176 - analytical standard, (E) and (Z) isomers (50:50)
Synonym: 4-
CAS Number: 68392-35-8
Empirical Formula (Hill Notation): C26H29NO2
Molecular Weight: 387.51
Linear Formula: C26H29NO2
Product Type: Chemical
| antibiotic activity spectrum | neoplastics |
| application(s) | forensics and toxicology pharmaceutical (small molecule) |
| form | powder |
| format | neat |
| grade | analytical standard |
| InChI | 1S/2C26H29NO2/c2*1-4-25(2 |
| InChI key | ZJLDABGSDWXVGE-BDSXMVAQSA |
| mode of action | enzyme | inhibits |
| Quality Level | 200  |
| SMILES string | CCC(c1ccccc1)=C(/c2ccc(O |
| solubility | ethanol: 20 mg/mL |
| technique(s) | gas chromatography (GC): suitable |
| HPLC: suitable |
| Application: | The 4-Hydroxytamoxifen analytical standard can be used as follows:• Determination of tamoxifen and its three metabolites from dried blood spot (DBS) discs by ultra-high performance liquid chromatography-electrospr • Simultaneous estimation of tamoxifen, 4-hydroxytamoxifen, and endoxifen from DBS samples by UHPLC-MS/MS • Development and validation of a non-aqueous capillary electrophoretic (NACE) method coupled with capacitively coupled contactless conductivity detection (C4D) to analyze tamoxifen and its three main metabolites after their liquid-liquid extraction (LLE) from human plasma samples obtained from breast cancer patients • Multi-residue analysis of human plasma samples to quantify tamoxifen and its degradation products using the non-aqueous capillary electrophoretic (NACE) method combined with UV-detection • Combined detection of tamoxifen and centchroman, along with their degradation products in human plasma samples by LC-ESI-MS/MS |
| Biochem/physiol Actions: | Metabolite of the chemotherapeutic drug tamoxifen, exhibiting more potent estrogen agonist/antagonist activity than the parent drug. Also active as intra-membranous inhibitor of lipid peroxidation. |
| General description: | 4-Hydroxytamoxifen is an antiestrogenic agent and one of the active metabolites of tamoxifen, formed upon its hydroxylation cytochrome P4502D6 (CYP2D6). Tamoxifen is used significantly in breast cancer as hormonal therapy. |
| Other Notes: | Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support. |
| Packaging: | 10, 50 mg in poly bottle |
| Symbol |   GHS07,GHS08 |
| Signal word | Warning |
| Hazard statements | H302 + H312 + H332 - H315 - H319 - H361 |
| Precautionary statements | P280 - P301 + P312 - P302 + P352 + P312 - P304 + P340 + P312 - P305 + P351 + P338 - P308 + P313 |
| Hazard Codes | Xn |
| Risk Statements | 63-20/21/22 |
| Safety Statements | 22-36 |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| UNSPSC | 41116107 |